Literature DB >> 6441511

Effect of azone and propylene glycol on penetration of trifluorothymidine through skin and efficacy of different topical formulations against cutaneous herpes simplex virus infections in guinea pigs.

S L Spruance, M McKeough, K Sugibayashi, F Robertson, P Gaede, D S Clark.   

Abstract

Tropical formulations of 5-trifluoromethyl-2'-deoxyuridine (TFT) containing different concentrations of TFT, Azone (Nelson Research and Development, Irvine, Calif.), and propylene glycol were evaluated for their potential efficacy in the treatment of cutaneous herpes simplex virus infections by in vitro studies of TFT penetration through skin and in vivo studies of therapeutic activity against herpes simplex virus type 1 infections in the dorsal cutaneous guinea pig model. Azone dramatically increased TFT penetration through human and guinea pig skin. Unexpectedly, high concentrations of propylene glycol were also associated with increased penetration. Studies in the guinea pig model revealed increased efficacy with Azone-propylene glycol-containing formulations, consistent with the in vitro drug diffusion results. A formulation containing 1% TFT, 5% Azone, and 80% propylene glycol decreased lesion area, in comparison to the drug vehicle control, more effectively than 5% acyclovir in polyethylene glycol (reduction of 70 versus 46%, P = 0.03). These studies demonstrate the value of penetration-enhancing agents and the need for careful preclinical evaluations in the development of topical antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6441511      PMCID: PMC180031          DOI: 10.1128/AAC.26.6.819

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  HEp-2 cell- and herpes simplex virus type 1- induced deoxythymidine kinases: inhibition by derivatives of 5-trifluoromethyl-2'-deoxyuridine.

Authors:  B L Wigdahl; J R Parkhurst
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Guinea pig model for cutaneous herpes simplex virus infection.

Authors:  W R Hubler; T D Felber; D Troll; M Jarratt
Journal:  J Invest Dermatol       Date:  1974-02       Impact factor: 8.551

3.  Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus.

Authors:  E De Clercq; J Descamps; G Verhelst; R T Walker; A S Jones; P F Torrence; D Shugar
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

4.  Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection.

Authors:  S L Spruance; M B McKeough; J R Cardinal
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Experimental herpes simplex virus type 1 encephalitis: treatment with 5-trifluoromethyl-2'-deoxyuridine.

Authors:  D W Clough; J R Parkhurst
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

6.  Enhanced percutaneous penetration with 1-dodecylazacycloheptan-2-one.

Authors:  R B Stoughton
Journal:  Arch Dermatol       Date:  1982-07

Review 7.  Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

8.  Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir.

Authors:  S L Spruance; C S Crumpacker; L E Schnipper; E R Kern; S Marlowe; K A Arndt; J C Overall
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Combined chemotherapy of cutaneous herpes simplex infection of the guinea pig.

Authors:  U Burkhardt; R Wigand
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

10.  The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.

Authors:  H Field; A McMillan; G Darby
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

View more
  5 in total

1.  The bioavailability of dermatological and other topically administered drugs.

Authors:  R H Guy; A H Guy; H I Maibach; V P Shah
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

2.  Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.

Authors:  E Bart Tarbet; Deanna Larson; Bentley J Anderson; Kevin W Bailey; Min-Hui Wong; Donald F Smee
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

3.  Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.

Authors:  S L Spruance; D J Freeman; N V Sheth
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

4.  Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.

Authors:  Spotswood L Spruance; Robert Nett; Thomas Marbury; Ray Wolff; James Johnson; Theodore Spaulding
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

5.  In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer Azone in excised human skin.

Authors:  E J Baker; J Hadgraft
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.